Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study - Top-Institutions - MDSpire

Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study

  • By

  • Xingmo Li

  • Jinxu Qi

  • Liping Shi

  • Lijuan Liu

  • Xiaoyu Xie

  • Guoqiang Zhang

  • Qing Zhu

  • April 20, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Psoriasis Foundation
    National Psoriasis Foundation

    Portland, Oregon

    Key Differentiators

    • Dermatology
    • Immunology
    • Psoriasis Research

  • #2

    Department of Dermatology, University of Pennsylvania (Perelman School of Medicine)
    Department of Dermatology, University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, Pennsylvania

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Trials

  • #3

    Department of Dermatology, Massachusetts General Hospital (Harvard Medical School)
    Department of Dermatology, Massachusetts General Hospital (Harvard Medical School)

    Boston, Massachusetts

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Research

  • #4

    Department of Dermatology, Stanford University School of Medicine
    Department of Dermatology, Stanford University School of Medicine

    Stanford, California

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Research

  • #5

    Department of Dermatology, University of California San Francisco (UCSF)
    Department of Dermatology, University of California San Francisco (UCSF)

    San Francisco, California

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

Original Source(s)

Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study

  • by Xingmo Li, Jinxu Qi, Liping Shi, Lijuan Liu, Xiaoyu Xie, Guoqiang Zhang, Qing Zhu

  • April 20, 2026

Related Content

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

UVB and Psoriasis: More Than Immunosuppression

UVB's benefits may run deeper than inflammation suppression—cholesterol metabolism could be a key link.